How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/germline-brca-mutated-her2-negative-metastatic-breast-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Germline BRCA-mutated, HER2-negative metastatic breast cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Germline BRCA-mutated, HER2-negative metastatic breast cancer (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Germline BRCA-mutated, HER2-negative metastatic breast cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Piqray	alpelisib	Novartis		PI3Kα	2019-01-01
Talzenna	talazoparib-tosylate	Pfizer	Poly(ADP-Ribose) Polymerase Inhibitor	PARP1, PARP2	2018-01-01
Talzenna	talazoparib	Pfizer	Poly(ADP-Ribose) Polymerase Inhibitor	Poly [ADP-ribose] polymerase 4	2018-01-01
Tecentriq	atezolizumab	Roche	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death 1 ligand 1	2016-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Germline BRCA-mutated, HER2-negative metastatic breast cancer
Novartis · 1 drug in Germline BRCA-mutated, HER2-negative metastatic breast cancer
Roche · 1 drug in Germline BRCA-mutated, HER2-negative metastatic breast cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Germline BRCA-mutated, HER2-negative metastatic breast cancer:

Cite this brief

Drug Landscape (2026). Germline BRCA-mutated, HER2-negative metastatic breast cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/germline-brca-mutated-her2-negative-metastatic-breast-cancer. Accessed 2026-06-10.

Germline BRCA-mutated, HER2-negative metastatic breast cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing